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•	 Prognostic Impact of KRAS 
Mutation Subtypes in 677 
Patients with Metastatic 
Lung Adenocarcinomas
KRAS transition versus transversion mutations (p = 
0.99), smoking status (p = 0.33), or specific amino acid 
substitutions (p = 0.20). Shorter overall survival was 
observed in patients with KRAS G13 mutation versus 
those with KRAS G12 mutations in univariate analysis 
(1.1 versus 1.3 years; p = 0.009) and multivariate 
analysis (hazard ratio = 1.52; p = 0.008). However, no 
survival difference between patients with KRAS G13 
and G12 mutations was found in an external multi-
institution validation cohort with stage IV KRAS-mutant 
lung cancers (n = 682; 1.0 versus 1.1 years; p = 0.41). 
To conclude, KRAS mutation subtypes do not seem to 
have any prognostic impact in this series of patients. 
Forthcoming investigation into concurrent mutations 
and variable gene expression could identify potential 
prognostic markers for patients with lung cancer with 
KRAS mutations. (p. 429)
The authors sought to determine the association between KRAS 
mutation subtypes and overall survival in 677 patients with KRAS-
mutant metastatic or recurrent lung cancers during a 6-year period. 
In this cohort of patients with KRAS mutation at G13 (n = 53) 
and G12 (n = 624), no overall survival difference was found in 
found in both multivariable and inverse probability 
of treatment weighting models (hazard ratio, 
0.87; p = 0.026 and hazard ratio, 0.89; p = 0.046, 
respectively). There was no interaction between 
the effects of PORT and number of involved lymph 
nodes (p = 0.615). Taken together, the findings 
suggest the survival benefits of PORT in this series 
of patients with pN2, which is in line with current 
practice guidelines indicating PORT is acceptable in 
addition to chemotherapy for patients with resected 
pN2. The observed benefits of PORT did not seem 
to be dependent on the number of involved lymph 
nodes. The authors cautioned the interpretation of the 
present retrospective study while anticipated results 
of a European prospective randomized trial (the Lung 
Adjuvant Radiotherapy Trial), which should be more 
definitive on the value of PORT in patients with pN2 
non–small-cell lung cancer. (p. 460)
•	 Postoperative 
RadioTherapy (PORT) Is 
Associated with Better 
Survival in Non–Small-Cell 
Lung Cancer with Involved 
N2 Lymph Nodes: Results 
of an Analysis of the 
National Cancer Data Base
This study assessed whether postoperative radiotherapy 
(PORT) may benefit patients with non–small-cell lung cancer 
and pathologically involved N2 (pN2) in a large retrospective 
cohort (n = 2115) from the National Cancer Data Base, who 
also received chemotherapy. PORT was given to 918 patients 
(43.3%), whereas 1197 (56.6%) did not receive PORT. 
Prolonged overall survival was observed in the PORT arm, with 
median survival time of 42 months versus 38 months in those 
without PORT (p = 0.048). Similar significant observation was 
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NSCLC tested for EGFR mutations in 2011 across 11 
Asia Pacific countries at 40 sites, which were used to 
complete on-line questionnaires. The data showed that 
EGFR mutation testing was performed on 31.8% of the 
patients, of which 39.6% were tested positive for EGFR 
mutations. The testing was performed on mainly biopsy 
and/or cytology samples (71.4%). The most commonly 
used testing method was DNA sequencing in 40% of 
tissue and 32.5% of cytology samples. Only 60% of 
the sites had a pathology report available, and 47.5% 
were not in a Quality Assurance Scheme. All in all, the 
findings warrant improvement to the molecular diagnosis 
of NSCLC, especially EGFR mutation testing practices 
that varied widely across Asia. (p. 436)
•	 EGFR Mutation Testing 
Practices within the Asia 
Pacific Region: Results of 
a Multicenter Diagnostic 
Survey
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In Asia, there was limited information on the number of patients with 
non–small-cell lung cancer (NSCLC) tested for EGFR mutations 
in each country, and the most commonly used testing methods. 
This retrospective study reviewed 22,193 records of patients with 
RESEARCH WATCH
•	 MET Amplification Status 
in Therapy-Naive Adeno- 
and Squamous Cell 
Carcinomas of the Lung
greater. Amplification of intermediate level was found in 
6% and of low level was found in 24% of the samples. 
Of note, MET amplifications were observed equally in 
squamous and adenocarcinomas regardless of EGFR 
or KRAS mutations. The findings suggest that MET 
amplification is not mutually exclusive in therapy-naive 
lung cancer and support evaluation of MET amplification 
before EGFR inhibitor treatment to determine potential 
resistance to anti-EGFR treatment and to select patients 
with KRAS mutations and MET amplification in which 
benefits from MET inhibitors might be limited. The 
comprehensive epidemiologic data from the study would 
be valuable for future studies on MET inhibitors.
Schildhaus H-U, Schultheis AM, Ruschoff J, et al. 
MET amplification status in therapy-naive adeno- and 
squamous cell carcinomas of the lung. Clinical Cancer 
Research, doi:10.1158/1078-0432.ccr-14–0450 (2014).
This study analyzed MET amplification status in 693 treatment-naive 
adenocarcinomas and squamous cell carcinomas of the lung with 
the aim of determining defined MET amplification scores and its 
epidemiologic data. Fluorescence in situ hybridization was used to 
study the prevalence of increased MET gene copy numbers, and the 
results were correlated to MET immunohistochemistry. No increase 
in MET gene copy numbers were found in 67% of lung cancers, 
whereas a clear-cut high-level amplification was found in 3%. Clear 
cutoff criteria were determined: MET/centromer 7 ratio of 2.0 or 
greater or average gene copy number per nucleus of 6.0 or greater, 
or 10% or greater of tumor cells containing 15 MET copies or 
associated with PCI (actuarial 5-year brain metastases 
rate: 20.3% versus 49.9%; p < 0.001). However, there 
was no significant difference in overall survival between 
the two arms (hazard ratio, 0.81; p = 0.310), most likely 
related to early termination of trial. Main toxicities 
observed were generally mild, including headache, 
nausea/vomiting, and fatigue in the PCI arm. All in all, 
the findings showed that PCI could prolong disease-free 
survival and reduce the incidence of brain metastases in 
patients with resected stage IIIA-N2 non–small-cell lung 
cancer and high risk of cerebral metastases after adjuvant 
chemotherapy.
Li N, Zeng, Z-F, Wang S-Y, et al. Randomized 
phase III trial of prophylactic cranial irradiation versus 
observation in patients with fully resected stage IIIA-N2 
non–small-cell lung cancer and high risk of cerebral 
metastases after adjuvant chemotherapy. Annals of 
Oncology, doi:10.1093/annonc/mdu567 (2014).
•	 Randomized Phase III 
Trial of Prophylactic 
Cranial Irradiation Versus 
Observation in Patients 
with Fully Resected Stage 
IIIA-N2 Non–Small-
Cell Lung Cancer and 
High Risk of Cerebral 
Metastases after Adjuvant 
Chemotherapy
This open-label, randomized, phase III study compared 156 patients 
with resected stage IIIA-N2 non–small-cell lung cancer and high risk 
of cerebral metastases after adjuvant chemotherapy, who received 
prophylactic cranial irradiation (PCI of 30 Gy in 10 fractions) or 
observation. The primary end point, disease-free survival, was 
significantly prolonged in the PCI arm versus the control arm 
(median 28.5 months versus 21.2 months; hazard ratio, 0.67; p = 
0.037). A significant decrease in risk of brain metastases was also 
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•	 Patient-Derived Xenografts 
from Non–Small-Cell 
Lung Cancer Brain 
Metastases Are Valuable 
Translational Platforms 
for the Development of 
Personalized Targeted 
Therapy
their in vivo brain metastatic potential. These cultured 
NSCLC brain metastatic PDX cells were tested for 
sensitivity against a library of 20 targeted agents that 
were included in the clinical guideline or on-going 
clinical trials for the treatment of NSCLC. Dramatic 
variation in efficacy of the agents was observed in the 
panel of cells tested, indicating a potential personalized 
strategy. PDXs derived from NSCLC brain metastases 
were consistent in in vivo engraftment rate and in 
vitro tumor sphere formation capacity, independent of 
clinical and molecular conditions, unlike those from 
primary NSCLC that was affected by histologic subtype, 
clinical aggressiveness, and genetic alterations. Taken 
together, the findings showed that PDXs from NSCLC 
brain metastases are reliable translational tools, which 
represent clinical situations with treatment-resistant or 
metastatic diseases. With the ability to retain biologic 
properties of corresponding individual tumors and 
represent heterogeneous advanced NSCLC population 
as well as to form tumor sphere in vitro, a PDX library 
of NSCLC brain metastases combined with a high-
throughput screen would be valuable for the validation 
of new drugs for personalized therapies in a more 
clinically relevant setting.
Lee HW, Lee J, Lee SJ, et al. Patient-derived 
xenografts from non–small-cell lung cancer brain 
metastases are valuable translational platforms for the 
development of personalized targeted therapy. Clin 
Cancer Res, doi:10.1158/1078-0432.ccr-14–1589 
(2014).
To meet the need of appropriate preclinical models for the 
development of novel therapeutic intervention for patients with 
non–small-cell lung cancer (NSCLC) brain metastasis, Lee et 
al. established patient-derived xenografts (PDXs) from resected 
NSCLC brain metastases and explored their potentials in developing 
personalized treatment. The PDX engraftment rate was significantly 
higher in NSCLC brain metastases (25 of 34, 74%) compared with 
that in primary tumors (15 of 64, 23%; p < 0.001). Histology and 
genomic analyses demonstrated that PDXs derived from NSCLC 
brain metastases retained the genetic, pathologic, and functional 
characteristics of the parental NSCLCs. Also, tumor spheres derived 
from PDX tumors in vitro under serum-free conditions preserved 
a 72% increase in caller number compared with that in 
2011. During the campaign, slightly higher number of 
uninsured callers was observed. Callers were also twice 
likely to be aware of the quitline from television media. 
Compared with individuals unaware of the campaign, 
those aware were slightly more likely to be non-Hispanic 
Black, aged less than 55 years, and uninsured. Taken 
together, the Tips campaign improved awareness of 
quitline services to the general population of smokers, 
across all demographic and tobacco use groups, and 
those uninsured in particular. Increased access to tobacco 
cessation services for the uninsured could potentially be 
achieved with Tips campaign and alike.
Zhang L, Vickerman K, Malarcher A, Carpenter K. 
Changes in quitline caller characteristics during a National 
Tobacco Education Campaign. Nicotine & Tobacco 
Research: official journal of the Society for Research on 
Nicotine and Tobacco, doi:10.1093/ntr/ntu271 (2015).
•	 Changes in Quitline Caller 
Characteristics dur-
ing a National Tobacco 
Education Campaign
This study assessed quitline data from 20 U.S. states and the 
District of Columbia for changes in caller characteristics, including 
demographics and smoking-related behaviors before and during the 
first federally funded national tobacco education campaign, “Tips 
From Former Smokers” (Tips) campaign. Characteristics of 76,933 
callers during the Tips campaign (March 19, 2012 to June 10, 2012) 
were compared with 44,710 callers from a similar time period in 
2011 (March 21, 2011 to June 12, 2011). Differences in self-reported 
awareness of Tips during the campaign were also examined in 13 
quitlines with a Tips awareness question. The results indicated a 
broad reach of the Tips campaign across demographic groups and 
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•	 The Importance of Product 
Definitions in U.S. e-Ciga-
rette Laws and Regulations
as smoking. Nicotine requirement for e-cigarette 
definitions was found in 16 states. More stringent local 
regulations were pre-empted in five states. The authors 
concluded that e-cigarette policies under local pre-
emption and definitions that separate e-cigarettes from 
tobacco products would compromise regulations. They 
urge policymakers to draft legislations that include 
broad definitions of e-cigarettes, no nicotine or tobacco 
requirement, no pre-emption of stringent laws, and 
explicit inclusion of e-cigarettes in smoke-free and 
taxation laws.
Lempert LK, Grana R, Glantz SA. The 
importance of product definitions in U.S. e-cigarette 
laws and regulations. Tobacco Control, doi:10.1136/
tobaccocontrol-2014–051913 (2014).
The authors set out to evaluate the definitions of e-cigarettes 
and similar products (e-cigarettes) in 46 bills in 40 states, which 
subsequently influence e-cigarette laws and regulation in sales, 
marketing, youth access, smoke-free, and taxation. The results 
found definitions commonly separate e-cigarettes from tobacco 
products using new product categories: 28 states with e-cigarettes 
excluded from tobacco products or smoking, only eight with 
e-cigarettes included as tobacco products and three included 
•	 The American Cancer 
Society (ACS) Cancer 
Statistics Report 2015
The American Cancer Society annual report showed a 
22% decline in cancer mortality in the United States 
during the past 2 decades and prevented more than 1.5 
million cancer deaths. The decline is attributed to reduced 
smoking, progress in cancer prevention, and early 
detection and treatment. Lung cancer mortality dropped 
by 36% among males (1990–2011) and 11% among 
females (2002–2011) as a result of reduced tobacco use. 
The most common causes of cancer death in males and 
females are lung, breast, prostate, and colorectal cancers, 
account for almost half of all cancer deaths, with 27% 
of all cancer deaths attributed to lung cancer. From 2007 
to 2011, the major decrease in cancer incidence in males 
were in cancers of colorectal (3.6% per year), lung (3.0% 
per year), and prostate (2.1% per year), whereas females 
have similar decline in colorectal and lung cancers, 
except breast cancer rate that levels off.
Image source: CDC
docetaxel for patients with metastatic non–small-
cell lung cancer, whose disease progressed on or 
after platinum-based chemotherapy. The approval 
was based on a multicenter, double-blind, placebo-
controlled, phase III trial (REVEL) in 1253 patients 
with metastatic non–small-cell lung cancer that 
showed a significantly prolonged overall survival in 
the ramucirumab/docetaxel combination arm versus 
the placebo/docetaxel combination arm (median 
overall survival, 10.5 months versus 9.1 months; 
hazard ratio, 0.86; p = 0.024). The ramucirumab/
docetaxel combination arm also achieved a 
significantly longer progression-free survival (hazard 
ratio, 0.76; p < 0.001).
NEWS IN BRIEF
•	 FDA Approves 
Ramucirumab 
Combination for Non–
Small-Cell Lung Cancer
Image source: NCI
The FDA granted approval of ramucirumab (antivascular 
endothelial growth factor receptor-2) in combination with 
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NEWS FROM THE 
IASLC TOBACCO 
CONTROL 
COMMITTEE
•	 British Heart Foundation 
(BHF) report on plain 
packaging
The British Heart Foundation has released a report on 
the effects of plain or standardized cigarette packaging 
(see link below) together with an analysis by Sir Cyril 
Chantler (eminent British pediatrician, see link below). 
The report presents compelling data from Australia 
which shows the effect of plain packaging on current 
smokers, with an increase (after introduction of plain 
packaging) in the percentage of smokers who support 
plain packaging, who notice health warnings more and 
who hate the look of their cigarette packs. The report 
recommends (in large print and red color) that with 
“clear evidence….and the pressing public health need, 
standardized packaging for tobacco products should be 
implemented without any further delay in the United 
Kingdom.” Sir Cyril’s review (which is far longer 
than the original report) concludes that “standardized 
packaging would serve to reduce the rate of children 
taking up smoking” and that “in conjunction with the 
current tobacco control regime…..[this would] have a 
positive impact on public health.
https://www.bhf.org.uk/~/media/files/publications/
campaigns/itc-british-heart-foundationa4-v8-web-final-
18dec2014.pdf
http://www.kcl.ac.uk/health/10035-TSO-
2901853-Chantler-Review-ACCESSIBLE.
PDF?utm_source=rss&utm_medium=rss&utm_
campaign=standardized-packaging-of-tobacco-report-
of-the-independent-review-undertaken-by-sir-cyril-
chantler-pdf
Image credit: CDC|Debora Cartagena
tobacco laws there. Public comment was invited during 
December on a proposal to ban indoor public space 
smoking, some bans on outdoor public spaces, banning 
of advertising and the introduction of graphic health 
warnings on packaging. A remarkable statistic presented 
in this report comes from a British Medical Journal 
study published in early 2014. This study calculates 
the prevention of 13 million premature deaths by 
2050 in China if all World Health Organization FCTC 
policies were to be implemented in a “complete and 
simultaneous” manner (BMJ. 2014 Feb 18;348:g1134. 
doi: 10.1136/bmj.g1134).
http://www.theunion.org/news-centre/news/
brazil-acts-to-further-curb-smoking-with-new-law
http://www.theunion.org/news-centre/news/
chinas-proposed-national-tobacco-control-law-now-up-
for-discussion
•	 New Laws Around the 
World: Brazil and China
The International Union against Tuberculosis and Lung Disease 
reports on new tobacco control legislation in Brazil and proposed 
legislation in China. Brazil has introduced bans on smoking in 
indoor public spaces, including public spaces in private residential 
buildings, as of December 3. And to follow on from China news 
in last month’s column, the Union also reports on proposed new 
404 Copyright © 2015 by the International Association for the Study of Lung Cancer
•	 Monitoring the Future 
(Zauche 12/12): Philip 
Morris, Snus, and the 
Future of Nicotine
and studies have not yet been published. And now there 
is snus (“snoose”), a tobacco product that you put in 
your mouth (but no chewing and therefore no spitting). 
Another NY Times article gives the background for 
this product. The company that markets snus, Swedish 
Match, is pushing for U.S. regulators to deem it less 
harmful than cigarettes. This report is lengthy and 
detailed and explores the arguments for and against 
the gentler health warnings, looking at tobacco use 
and tobacco disease statistics from Sweden (both have 
fallen since the 1970s). The clearest message that 
comes from constant reading and writing about tobacco 
control is that it is complex, multipronged, inventive, 
and matched only by the multipronged inventiveness of 
the tobacco industry itself with new delivery systems, 
legal maneuvers detailed in previous columns and a 
dogged refusal to abandon or renounce the continued 
manufacture and sale of a toxic and addictive substance.
http://www.nytimes.com/2014/12/25/business/
race-to-deliver-nicotines-punch-with-less-risk.html?_r=2
http://www.nytimes.com/2014/11/30/business/
maker-of-snus-a-smokeless-tobacco-says-its-less-
harmful-than-cigarettes.html?_r=0
A report in the New York Times, published on Christmas Eve, 
explores the possible future of the tobacco (or nicotine) industry. 
It carries a gleaming high-tech imagine of Philip Morris scientists 
hard at work on new nicotine delivery possibilities. What are 
they up to? Well, there are e-cigarettes, largely made by tobacco 
companies and now carrying higher nicotine levels, ostensibly (to 
quote Dr. Patrick Picavet the director of clinical assessment for 
PMI) “to reduce risks and…[to provide] acceptable substitutes” 
for cigarettes. The article lists major e-cigarette manufacturers and 
carries links to other reports on the e-cigarette debates. And there 
are other things on the horizon. Have you heard of iQOS, new 
devices which heat tobacco sticks to a vapor to produce plenty of 
nicotine? The toxicity of these devices is subject to investigation, 
